Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...

Hospitals paradoxically house fast food outlets, raising health concerns. A U.S. poll shows most oppose such sales; India too ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma: Paris Friday, August 1, 2025, 09:00 Hrs [IST] The US ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for SAR446523, an ...

| Jul. 25, 2025 09:00Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering PR Newswire Jul. 25, 2025 09:00 ...

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong ...